Gynecologic Cancer
The prospective case series demonstrates the efficacy of the combination in second- and later-line treatment.
Targeted therapies directed toward tumor genotype should be considered in addition to standard-of-care regimens.
New biomarker 2,3,6-trichlorobenzaldehyde shows 95% accuracy in blood tests for early cervical cancer and CIN detection.
Menstrual blood HPV testing shows 100% match with cervical smears—non-invasive, accurate, and preferred by most women.
Tumor mutations were even detected in early-stage disease.
The findings reaffirm concurrent chemoradiotherapy as a cornerstone of treatment.
Researchers assessed ICD gene expressions to predict immunotherapy response and immune cell infiltration.
The global burden of cervical cancer, as well as cervical cancer mortality, is predicted to increase substantially by 2030.
Subgroup analyses of multiple diagnostic performance metrics in high vs low-income communities were also performed.
A study compared the screening performances of a tools used in cervical cancer screening in HIV-positive women.
Advertisement
Expert Interviews on Oncology
Advertisement
DocWire News delivers the latest medical industry news, giving health care professionals the curated content most relevant to their fields and practices.
Get the latest medical updates and insights straight to your inbox.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.